Neuroimmunology Unit, Medical School, University of Tampere and Tampere University Hospital, Tampere, Finland.
J Neuroimmunol. 2011 May;234(1-2):141-7. doi: 10.1016/j.jneuroim.2011.02.009. Epub 2011 Mar 11.
To identify biomarkers of disease activity and progression in multiple sclerosis (MS), we analyzed the serum profiles of cytokines, chemokines and apoptotic molecules in different subtypes of MS including clinically isolated syndrome (CIS) and correlated their levels with clinical and volumetric MRI findings obtained over a one-year follow up. Upregulated levels of apoptotic sFas molecule were found in MS patients with a worsening EDSS score and an accumulation of hypointense lesions in MRI. In such patients, the levels of MIF appeared to be higher than in non-progressing patients. In addition, increased levels of serum TNF-α and CCL2 were found especially in primary progressive MS (PPMS). These observations suggest that serum Fas and MIF are candidate biomarkers of neurological worsening related to progressive neurodegeneration, while serum TNF-α and CCL2 reflect the presence of inflammatory responses in PPMS.
为了鉴定多发性硬化症(MS)中疾病活动和进展的生物标志物,我们分析了不同 MS 亚型(包括临床孤立综合征(CIS))的血清细胞因子、趋化因子和凋亡分子谱,并将其水平与在一年随访期间获得的临床和容积 MRI 结果相关联。我们发现,在 EDSS 评分恶化和 MRI 出现低信号病灶累积的 MS 患者中,凋亡 sFas 分子的水平上调。在这些患者中,MIF 的水平似乎高于无进展患者。此外,血清 TNF-α 和 CCL2 的水平在原发性进展性 MS(PPMS)中尤其升高。这些观察结果表明,血清 Fas 和 MIF 是与进行性神经退行性变相关的神经恶化的候选生物标志物,而血清 TNF-α 和 CCL2 反映了 PPMS 中炎症反应的存在。